Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.41 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.40 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | ITK | Q08881 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13987019 | 0.82 | GSK3B (0.50) | HDAC1GSK3BHDAC2HDAC3DYRK1A | |
| SCHEMBL4851380 | 0.78 | GSK3B (0.58) | HDAC1GSK3BHDAC2HDAC3GSK3A | |
| SCHEMBL13987014 | 0.77 | GSK3B (0.50) | HDAC1GSK3BHDAC2HDAC3DYRK1A | |
| SCHEMBL1750449 | 0.74 | GSK3B (0.61) | HDAC1GSK3BHDAC2HDAC3DYRK1A | |
| SCHEMBL4856612 | 0.72 | GSK3B (0.49) | GSK3B | |
| SCHEMBL13987016 | 0.72 | MAPT (0.47) | GSK3BDYRK1AGSK3A | |
| SCHEMBL13986950 | 0.72 | GSK3B (0.59) | HDAC1GSK3BHDAC2HDAC3DYRK1A | |
| SCHEMBL27707706 | 0.71 | HDAC2 (0.46) | HDAC1HDAC2HDAC3IKBKETBK1 | |
| SCHEMBL4854637 | 0.71 | GSK3B (0.55) | HDAC1GSK3BHDAC2HDAC3DYRK1A | |
| SCHEMBL14375208 | 0.70 | GSK3B (0.47) | HDAC1GSK3BHDAC2HDAC3DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754713-B2 | 4-benzimidazol-2-ylpyridazin-3-one derivatives | AVENTIS PHARMA S.A. (FR) | 2010-07-13 | — | — | US | disclosed |
| US-7727989-B2 | 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-01 | — | — | US | disclosed |
| US-20090042880-A1 | NOVEL 4-BENZIMIDAZOL-2-YLPYRIDAZIN-3-ONE DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 2009-02-12 | — | — | US | disclosed |
| US-7470689-B2 | 4-benzimidazol-2-ylpyridazin-3-one derivatives | AVENTIS PHARMA S.A. (FR) | 2008-12-30 | — | — | US | disclosed |
| US-20070173503-A1 | Novel 4-benzimidazol-2-ylpyridazin-3-one derivatives | AVENTIS PHARMA S.A. (FR) | 2007-07-26 | — | — | US | disclosed |
| US-20070072866-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-29 | — | — | US | disclosed |
| EP-1723137-A1 | NOVEL 4-BENZIMIDAZOL-2-YLPYRIDAZIN-3-ONE DERIVATIVES | Aventis Pharma S.A. (FR) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005085231-A1 | NOVEL 4-BENZIMIDAZOL-2-YLPYRIDAZIN-3-ONE DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173503-A1 | Novel 4-benzimidazol-2-ylpyridazin-3-one derivatives | CDK2, CDK1, CDK4 | HDAC1 438/4885GSK3B 724/4885HDAC2 421/4885 |
| US-20070072866-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | GSK3B, GSK3A, PYGB | HDAC1 548/4885GSK3B 1/4885HDAC2 590/4885 |
| US-20090042880-A1 | NOVEL 4-BENZIMIDAZOL-2-YLPYRIDAZIN-3-ONE DERIVATIVES | CDK2, CDK1, CDK4 | HDAC1 465/4885GSK3B 757/4885HDAC2 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.